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Amyloid -peptide (A), which plays a central role in
Alzheimer’s disease, is generated by presenilin-
dependent -secretase cleavage of -amyloid precur-
sor protein (APP). We report that the presenilins
(PS1 and PS2) also regulate A degradation. Preseni-
lin-deficient cells fail to degrade A and have drastic
reductions in the transcription, expression, and activ-
ity of neprilysin, a key A-degrading enzyme. Nepri-
lysin activity and expression are also lowered by
-secretase inhibitors and by PS1/PS2 deficiency in
mouse brain. Neprilysin activity is restored by tran-
sient expression of PS1 or PS2 and by expression
of the amyloid intracellular domain (AICD), which is
cogenerated with A, during -secretase cleavage of
APP. Neprilysin gene promoters are transactivated
by AICDs from APP-like proteins (APP, APLP1, and
APLP2), but not by A or by the -secretase cleavage
products of Notch, N- or E- cadherins. The presenilin-
dependent regulation of neprilysin, mediated by
AICDs, provides a physiological means to modulate
A levels with varying levels of -secretase activity.*Correspondence: checler@ipmc.cnrs.frIntroduction
One of the two main histopathological hallmarks in Alz-
heimer’s disease (AD) is the senile plaque, an extracel-
lular protein deposit composed in part by fibrillar aggre-
gates of amyloid β-peptides (Aβ) (Haass and Selkoe,
1993). Aβ is a 40–42 amino acid peptide that is gener-
ated from the β-Amyloid Precursor Protein (βAPP) by
two sequential cleavages. The first of these cleavages
occurs in the extracellular domain and is mediated by
a membrane-bound aspartyl protease termed β-secre-
tase (Vassar and Citron, 2000). The second set of cleav-
ages occurs at residues 40–42 (termed γ-site) and at
residues 48–52 (termed -site) within the transmem-
brane domain of the βAPP stub generated by β-secre-
tase. The γ-site cleavage generates Aβ, while the con-
current -site cleavage generates a cytosolic stub
referred to as ICD (Passer et al., 2000) or AICD (βAPP
IntraCellular Domain). The exact role of AICD remains
unclear.
Both the γ- and the -site cleavages are mediated by
presenilin (PS)-independent and dependent proteases
(De Strooper et al., 1998; Armogida et al., 2001). The
presenilin-dependent γ-secretase and -site proteolytic
activities (which are often generically collectively termed
γ-secretase) are dependent upon a multimeric complex
of at least four different membrane proteins including
Presenilin 1(PS1) or Presenilin 2 (PS2), nicastrin, Aph-1,
and Pen-2 (Yu et al., 2000; Francis et al., 2002). In these
complexes, the presenilins have been proposed as a
novel type of transmembrane aspartyl protease bearing
the catalytic core of the γ-secretase (Wolfe et al., 1999).
This novel type of intramembranous proteolysis ap-
parently governs the function of βAPP and several Type
I transmembrane proteins including Notch, cadherins,
ErbB-4, CD44, or p75NTR. Many of these proteins are
involved in a variety of vital cellular functions such as
intracellular signaling in development and adulthood,
cell adhesion, cell growth and proliferation, and kinase
activities (for review see Sisodia and St. George-Hys-
lop, 2002; Pollack and Lewis, 2005). Thus, γ-secretase
cleavage of Notch releases an intracellular fragment
called NICD (Notch IntraCellular Domain), which acts
as a transcription factor mediating signal transduction
in the Notch-Delta pathway, a critical intercellular sig-
naling mechanism, during both embryonic develop-
ment and adulthood (Kopan et al., 1996; Shen et al.,
1997; De Strooper et al., 1998; Kopan and Goate, 2000).
Under normal conditions, Aβ occurs as a soluble
fragment, the concentration of which is normally tightly
controlled below the threshold for its self-aggregation
into β sheet fibrils (Burdick et al., 1992). Aβ is actively
degraded by several enzymes including neprilysin
(NEP), insulin-degrading enzyme (IDE), and endothelin-
converting enzyme (ECE) (Carson and Turner, 2002). Al-
though these Aβ-degrading enzymes have been well
characterized, very little is known about the regulatory
mechanisms that govern their expression and/or activ-
ity. Nevertheless, under normal physiological circum-
stances, the balance between the rates of production
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542and clearance of Aβ is likely to be delicately regulated, n
obreaking down only in circumstances that lead to the
ronset of Alzheimer’s disease. We show here that al-
ithough γ-secretase cleavage produces Aβ, the other
dproduct of γ-secretase cleavage (AICD) specifically
lupregulates the transcription of NEP, which in turn, ac-
ncelerates the degradation of Aβ. This transcriptional
csignaling pathway therefore provides a simple and ele-
tgant physiological mechanism for the regulation of Aβ






Neprilysin Expression and Activity Are Reduced 0
in Cells Devoid of Presenilins s
Aβ40 immunoreactivity decreases in a time-dependent i
manner upon exposure of exogenous Aβ40 peptide to 5
wild-type fibroblasts and blastocysts (PS+/+ and BD6, b
Figure 1A). This decrease could be blocked by phos- k
phoramidon (Suda et al., 1973), a specific inhibitor of n
neprilysin (not shown). However, we observed that b
Aβ40 was not efficiently degraded by PS-deficient fi- 1
broblasts or by PS-deficient blastocysts (PS−/− and
bBD8, Figure 1A). These results raise the possibility thatFigure 1. Neprilysin Expression and Activity Are Selectively Lowered in Presenilin-Deficient Cells
(A) Synthetic Aβ40 was incubated for various time periods with the indicated wild-type or PS-deficient cells; then Aβ-related immunoreactivity
was analyzed after 16.5% Tris-tricine electrophoresis and Western blot with WO2.
(B–J) Neprilysin activity was measured in fibroblasts (B, D, and H) or blastocyst-derived (C, F, and J) homogenates (B–D and F) or intact cells
(H and J). Neprilysin corresponds to total (white bars in [D] and [F]) or phosphoramidon-sensitive (B, C, H, and J) Suc-Ala-Ala-Phe-7AMC-
hydrolyzing activity. Neprilysin-like immunoreactivity was monitored in whole homogenates (E and G) or by immunohistochemical labeling on
intact fibroblasts (I). Bars represent the mean ± SEM of six (D), nineteen (F), three (H), or sixteen (J) independent determinations. *p < 0.001;
**p < 0.0001.
(K–N) Neprilysin (NEP)-, endothelin-converting enzyme (ECE)-, and insulin-degrading enzyme (IDE)-like immunoreactivities were monitored in
homogenates of PS+/+ and PS−/− fibroblasts (K). Aminopeptidase M (L), proteasome (M), and calpain (N) activities were measured on the
indicated intact cells (L) or in fibroblast cell homogenates (M and N). Bars in (L)–(N) represent the mean ± SEM of ten (L) or three (M and N)
independent determinations.eprilysin activity might be modulated, either directly
r indirectly, by the presenilins. This hypothesis was di-
ectly supported by the subsequent observation that,
n comparison with wild-type cells, PS-deficient cells
isplayed dramatically lower levels of total neprilysin-
ike activity, phosphoramidon-sensitive activity, and
eprilysin protein expression. In Figures 1D and 1F,
omparison of the white bars reveals the difference in
otal neprilysin-like activity: 12450 ± 934 versus 2148 ±
26 for fibroblasts (Figure 1D; p < 0.0001) and 15450 ±
54 versus 11160 ± 672 for blastocysts (Figure 1F; p <
.0001). Similarly, phosphoramidon-sensitive activity is
ower in PS-deficient cells: 10480 ± 771 versus 1029 ±
19 for fibroblasts (Figure 1D; p < 0.0001) and 13730 ±
49 versus 9149 ± 672 for blastocysts (Figure 1F; p <
.0001). The same held for neprilysin protein expres-
ion: 29% ± 5.4% of control expression was observed
n PS−/− fibroblasts (Figure 1E, n = 7; p < 0.0001) and
1% ± 3% of control expression was observed in PS−/−
lastocysts (Figure 1G, n = 11; p < 0.0001). Note that
inetic analyses indicated that NEP activity was sig-
ificantly lower at all time points in PS-deficient fibro-
lasts (Figure 1B; p < 0.0001) and blastocysts (Figure
C; p < 0.0001).
Because neprilysin is a typical type II membrane-
ound peptidase (Roques et al., 1993), we next exam-
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543ined neprilysin activity on the surface of intact cells,
using a cell-impermeable fluorimetric substrate. In this
assay, the substrate is cleaved only by enzymes that
are present at the cell surface with their catalytic sites
facing the extracellular space. In agreement with the
studies on whole-cell lysates described above, PS-
deficient fibroblasts exhibited a significant 80% reduc-
tion of cell membrane neprilysin activity compared to
that in wild-type fibroblasts (31130 ± 582 versus 4609
± 359, Figure 1H; p<0.0001). Furthermore, neprilysin im-
munoreactivity was poorly detectable at the surface of
intact PS-deficient fibroblasts, although it was readily
detectable on the surface of wild-type fibroblasts (Fig-
ure 1I). A similar reduction in cell membrane neprilysin
activity was also observed in PS-deficient blastocysts
(BD8), but not in wild-type blastocysts (BD6) (380.7 ±
34 versus 199 ± 25, Figure 1J; p < 0.001).
Presenilin Deficiency Selectively Affects Neprilysin
To assess whether PS deficiency specifically altered
neprilysin activity, or whether it also affected other pu-
tative Aβ-degrading activities or proteases, we mea-
sured the expression of endothelin-converting enzyme
and insulin-degrading enzyme (Figure 1K) and the
activities of aminopeptidase M, another ectoenzyme
(Figure 1L) (Checler, 1993), proteasome (Figure 1M),
and calpain (Figure 1N). In sharp contrast to the effects
of PS-deficiency on neprilysin, none of these other en-
zymes were affected by the absence of PS1 and PS2.
Presenilin 1 and Presenilin 2 Affect
Neprilysin Transcription
The presenilins directly interact with several unrelated
proteins such as nicastrin, Aph-1, and Pen-2, and many
of these proteins are destabilized by the absence of the
presenilins (for review, see De Strooper, 2003). How-
ever, six lines of evidence indicate that the reductions
in neprilysin in PS-deficient cells are not due to the loss
of a direct, stabilizing interaction between the preseni-
lin and neprilysin proteins, but rather arise from a re-
duction of neprilysin transcription. First, anti-NEP im-
munoprecipitates from wild-type fibroblasts do not
contain PS1 (Figure 2A) or PS2 (not shown). Second,
PS1 and PS2 immunoprecipitation does not deplete su-
pernatants of NEP activity (not shown). Third, residual
NEP expression in PS−/− fibroblasts partitioned within
cell compartments with the same distribution as in
wild-type fibroblasts (Figure 2B), suggesting that PS
deficiency did not alter trafficking of NEP in PS−/− fibro-
blasts. Fourth, neprilysin stability is not affected by PS
deficiency (Figure 2C). Fifth, both neprilysin expression
and cell surface neprilysin activity can be fully restored
by transfection of neprilysin cDNA into PS-deficient fi-
broblasts (Figure 2D) and into PS-deficient blastocysts
(120% ± 4.6% above control mock-transfected cells;
p < 0.01; data not shown). Finally, quantitative RT-PCR
analyses revealed an approximately 80% reduction in
neprilysin mRNA (Figure 3A) (note that overexposure of
the gel [lower panel] shows residual mRNA expression).
Taken together, these data suggest that the loss of
neprilysin expression in PS-deficient cells arises from
impairment in neprilysin transcription. Intriguingly, nep-
rilysin transcription, protein expression, and enzymaticFigure 2. Presenilin Deficiency Does Not Affect Neprilysin at a Post-
transcriptional Level
(A) NEP was immunoprecipitated from PS+/+ and PS−/− fibroblast
homogenates. Immunological complexes were analyzed for their
endogenous NEP and PS1-like immunoreactivities. Note that PS1-
like immunoreactivity corresponds to the C-terminal maturation
product of PS1 (CTF-PS1; Checler, 1999).
(B) Endogenous cell distribution of NEP was analyzed by sucrose
density gradient. Note that NEP immunoreactivity is drastically
lower in PS−/− fibroblasts (while control β-actin is identical) and
that residual NEP behaves as in PS+/+, i.e., like the ectoenzyme
ADAM10.
(C) PS+/+ and PS−/− fibroblasts were treated with cycloheximide to
prevent NEP neosynthesis as described in the Experimental Pro-
cedures. At the indicated times, NEP activity was fluorimetrically
recorded. Note the identical slopes (−1.65 ± 0.22 [PS+/+] and
−1.35 ± 0.31 [PS−/−]), indicating a PS-independent similar decay of
NEP (each point is the mean ± SEM of three independent determin-
ations). Upper panel shows NEP immunoreactivity decrease in
PS+/+ fibroblasts.
(D) Forty-eight hours after transfection in PS+/+ and PS−/− fibro-
blasts, NEP expression (upper panel) and activity (lower panel)
were monitored as described in the Experimental Procedures. Bars
represent the mean of two independent experiments carried out
in duplicate.activity were not affected in cells devoid of either PS1
only or PS2 only. Thus, normal levels of neprilysin
mRNA (Figure 3A), enzymatic activity (Figure 3B), and
protein expression (Figure 3C) were observed in PS1−/−
fibroblasts (expressing only endogenous PS2) and in
PS2−/− fibroblasts (expressing only endogenous PS1).
Identical results were achieved when exogenous PS1
or exogenous PS2 were transfected into PS-deficient
fibroblasts. Thus, neprilysin mRNA expression, protein
expression, and enzymatic activity were equivalently
and fully restored in PS-deficient fibroblasts by tran-
sient transfection of PS1 and PS2, PS1 only, or PS2
only (Figures 3D and 3E). Control experiments indicate
that aminopeptidase M activity was not affected by
PS1 or PS2 complementation in PS-deficient fibro-
blasts (Figure 3F). These data were fully confirmed
Neuron
544Figure 3. NEP mRNA Expression Is Reduced in PS-Deficient Cells and Restored by Either PS1 or PS2. NEP Is Reduced in Brain Tissue from
Conditional Knockout Mice Lacking Both Presenilins
(A) Analysis of NEP mRNA expression by RT-PCR in PS+/+, PS1−/−, PS2−/−, and PS1−/−/PS2−/− (PS−/−) fibroblasts. Note that only the combined
depletion of PS1 and PS2 reduces NEP mRNA expression by 80% (lower panel, an overexposed gel analysis), while PS1 or PS2 invalidation
does not affect NEP mRNA expression.
(B and C) PS1−/− and PS2−/− fibroblasts display unaffected NEP activity (B) and expression (C). Data in (B) represent the mean ± SEM of five
independent determinations.
(D and E) PS−/− fibroblasts were transiently transfected with PS1, PS2, or both (PS1/2) cDNAs, and then NEP mRNA and protein (D) or activity
(E) was monitored. Note that PS1 or PS2 cDNA alone fully restores NEP mRNA expression as well as NEP expression and activity. Bars in (E)
represent the mean ± SEM of three independent determinations.
(F) In the same PS−/− transfected cells, aminopeptidase M activity remains unaffected. Bars represent the mean of two independent determin-
ations.
(G–J) PS1−/− (G) and double KO PS1−/−PS2−/− (H–J) mice brains were homogenized and examined for NEP activity (G and J) or expression (I).
Bars in (H) correspond to the densitometric analysis of NEP expression in three independent determinations; *p < 0.05. Bars in (G) and (J)
correspond to the mean of three independent determinations; **p < 0.01.in vivo because PS1-deficiency did not alter brain nep- t
trilysin activity (Figure 3G), while neprilysin expression
F(Figures 3H and 3I) and activity (Figure 3J) were simi-
olarly and significantly reduced in brain tissue from con-
aditional double knockout mice lacking both presenilins
i(41% ± 9% and 29% ± 2.3% inhibition of NEP expres-
Dsion and activity, respectively, n = 3; p < 0.05 in PS−/−
aversus control brain). These data therefore lead to the
(conclusion that PS1 and PS2 may have redundant roles
ain regulating neprilysin transcription, but depletion of




-Secretase Inhibitors Reduce Neprilysin Activity u
in Neuronal and in Wild-Type Cells but Not n
in PS-Deficient Fibroblasts (
The reduction in neprilysin transcription in PS-deficient s
cells could arise from loss of presenilin-dependent
γ-secretase activity or from loss of some other putative A
activity of the presenilin complexes. To resolve this ques- E
tion, we examined whether neprilysin activity could be B
directly modulated in wild-type cells by γ-secretase in- T
ahibitors. Chronic treatment of wild-type fibroblasts withhe γ-secretase inhibitor DAPT (Dovey et al., 2001) led
o a 50% inhibition of neprilysin activity (p < 0.0001,
igure 4A). The inhibitory effect was maximal at 48 hr
f treatment, a time point at which DAPT was inert on
minopeptidase activity (Figure 4B). Other γ-secretase
nhibitors, namely L685,458 (Shearman et al., 2000) or
FK167 (referred to as MW167 in Wolfe et al. [1998])
lso elicited significant reduction of neprilysin activity
p < 0.001 and p < 0.05, respectively, Figure 4C), while
control calpain inhibitor (CPI) was totally ineffective
Figure 4C). Importantly, DFK167 also lowers neprilysin
ctivity in TSM1 neurons (30.4% ± 3.8% of inhibition
ersus control, n = 5; p < 0.0001, Figure 4E) and in pri-
ary cultured neurons (56.3% of inhibition, n = 2, Fig-
re 4F). All inhibitors remain inactive on the residual
eprilysin activity observed in PS-deficient fibroblasts
Figure 4D) and do not affect in vitro NEP activity (not
hown).
ICDs Upregulate Neprilysin Activity and
xpression in PS-Deficient Fibroblasts and
lastocysts and Neprilysin Promoter Transactivation
he canonical γ-secretase-mediated hydrolysis liber-
tes the C terminus of Aβ40/42 and concomitantly re-
Presenilins Regulate Neprilysin Transcription
545Figure 4. Effect of γ-Secretase Inhibitors and γ-Secretase-Derived βAPP Fragments on NEP Activity and Promoter Transactivation
(A–F) Wild-type (PS+/+) fibroblasts were chronically treated by successive additions of DAPT for a total time period of 8, 24, and 48 hr (see
Experimental Procedures) (A) or for 48 hr (B) with 2 M of DAPT, and then NEP (A) or aminopeptidase M (B) activities were fluorimetrically
recorded on intact cells. Error bars represent the mean ± SEM of three to six independent determinations. PS+/+ (C), PS−/− fibroblasts (D),
TSM1 neurons (E), and primary cultured neurons (F) were treated with the indicated inhibitor (DAPT, 48 hr, 2 M; L685,458, 8 hr, 1 M;
DFK167, 8 hr, 100 M; calpain inhibitor [CPI], 8 hr, 100 M), and then the NEP activity of intact cells was measured. Error bars represent the
mean ± SEM of three to five independent determinations; ***p < 0.0001.
(G–K) PS-deficient (PS−/−) fibroblasts or PS-deficient (BD8) blastocyst-derived cells (G) were treated for various time periods with 10 ng/ml of
Aβ42, and then NEP activity was fluorimetrically assayed on intact cells. Error bars represent the mean ± SEM of three experiments. PS−/−
fibroblasts (H and J) or BD8 cells (I and K) were transiently transfected with empty vector or with the indicated AICD cDNA , and then NEP
activity (H and I) or expression (J and K) was monitored. Bars in (H) and (I) represent the mean ± SEM of five independent experiments.
(L and M) The indicated AICD was cotransfected in fibroblasts (L) or in TSM1 neurons (M) with β-gal cDNA and either renal NEP promoters
rNEPP1 and rNEPP2 (L) or neuronal NEP promoter nNEPP (M), and then β-galactosidase and luciferase activities were monitored.
(N) HEK293 cells were transfected with AICDC59, Fe65, and Tip60 cDNA , and then nuclear extracts and binding experiments with the 219
bp probe derived from rNEPP were carried out as described in the Experimental Procedures. Lane 1, labeled probe + nuclear extract; lane 2,
labeled probe + nuclear extract + Anti-myc; lane 3, labeled probe + nuclear extract + unrelated antibody.leases the 59 amino acid stub composed of the cyto-
plasmic C-terminal tail of βAPP referred to as AICDC59
(see Introduction and Figure 8). An additional prese-
nilin-dependent proteolytic cleavage of βAPP and
Notch occurs several amino acids downstream (re-
ferred to as  cleavage). This  cleavage event liberates
AICDC50 from APP and a Notch IntraCellular Domain
(NICD) from Notch (Gu et al., 2001; Sastre et al., 2001;
Weidemann et al., 2002). Because NICD is known to
modulate the transcription of several genes, we rea-
soned that neprilysin transcription might be modulated
by one of the γ/-secretase-derived products. Exoge-
nous Aβ42 did not modify neprilysin activity in PS-defi-
cient fibroblasts or in PS-deficient blastocysts (Figure
4G). However, transient transfections of AICDC50 or
AICDC59 cDNAs increased both neprilysin activity (Fig-
ures 4H and 4I) and neprilysin expression (Figures 4J
and 4K) in PS-deficient fibroblasts and blastocysts.
In order to link our observation of AICD-induced in-
crease of neprilysin activity and expression to our ob-
servation of PS-dependent neprilysin mRNA upregula-
tion, we examined the effect of AICDC50 and AICDC59
on neprilysin promoter transactivation, using variousneprilysin promoter elements upstream of a luciferase
reporter minigene. Both AICDs dramatically increased
the transactivation of two renal neprilysin promoters,
rNEPP1 (−385 bp to +147 bp) and rNEPP2 (−263 bp
to +145 bp, Figure 4L) in fibroblasts. To confirm AICD-
induced transactivation of the neprilysin promoter in a
neural cell line, we also cloned the neuronal neprilysin
promoter and repeated the luciferase reporter assay. In
agreement with the above observations, AICDC50 also
transactivated neprilysin promoter in TSM1 neurons
(Figure 4M). Supergel shift assay analysis demon-
strated that the AICD-potentiated transactivation of the
neprilysin promoter indeed appears to be mediated by
a direct physical interaction of AICD with the neprilysin
promoter (Figure 4N).
AICD-Induced Complementation of Neprilysin
Activity Is Potentiated by Fe65 and Tip60
in Fibroblasts and in HEK293 Cells
Several lines of evidence have indicated that the adap-
tor protein Fe65 modulates the stability of AICD (Kim-
berly et al., 2001; Kinoshita et al., 2002), thereby po-
tentiating its subsequent nuclear translocation and
Neuron
546interaction with the histone acetyltransferase Tip60 T
F(Cao and Südhof, 2001). We therefore examined whether
Fe65 and Tip60 could (1) influence neprilysin by modu- r
alating endogenous AICD in wild-type fibroblasts and in
HEK293 cells and (2) potentiate AICD-induced increase t
iin neprilysin activity.
Fe65 and Tip60 transfection enhanced neprilysin ex- H
wpression and activity in PS+/+ fibroblasts (Figure 5A [up-
per panel] and Figure 5C; p < 0.0005) and in HEK293 p
icells (Figure 5A [lower panel]), but not in PS-deficient
cells (Figures 5B and 5C), indicating that Fe65 and i
sTip60 augment neprilysin expression through functional
interaction with an endogenous PS-dependent prod- i
2uct. In wild-type PS+/+ fibroblasts, the cotransfection of
Fe65 and Tip60 with either AICDC50 or AICDC59 cDNA i
fincreased neprilysin expression when compared to
AICDs cDNA transfection alone (Figure 5A). This was p
caccompanied by an augmentation of AICDC50 and
AICDC59 immunoreactivities (Figure 5A [lower panel])
Xand by a clear translocation of AICDC59 (Figure 5D)
and AICDC50 (not shown) into the nuclei of HEK293 w
1cells and PS+/+ fibroblasts (not shown). Similar potenti-
ation of neprilysin expression by Fe65 and Tip60 trans- H
rfection was also observed in AICD-transfected PS-defi-
cient fibroblasts (136% ± 6%, AICDC50+Fe65+Tip60 X
versus AICDC50 alone and 135% ± 6.2%, AICDC59+
Fe65+Tip60 versus AICDC59 alone; p < 0.0005). Inter- 
testingly, AICDC50 and AICDC59 increase renal nepri-
lysin promoter transactivation in HEK293 cells (not TFigure 5. Effect of Fe65 and Tip60 on NEP in Fibroblasts and HEK293 Cells
(A–C) PS+/+ ([A], upper panel and [C]) and PS−/− (B and C) fibroblasts were transiently transfected with the indicated mix of cDNAs; then NEP,
ECE, IDE, Fe65, and β−tubulin expressions were measured by Western blot. (Note that gel in [B] corresponds to a long exposure in order to
visualize any putative effect of Fe65 and Tip60 on residual NEP). Densitometric analyses (C) indicate that transfection of Fe65 and Tip60
cDNAs alone increases NEP expression in PS+/+ (p < 0.0005 when compared to vector alone) but not in PS−/−. Error bars in (C) represent the
mean ± SEM of four independent determinations. (A, D, and F) HEK293 ([A], lower panel, [D], and [F]) were transiently transfected with the
indicated mix of cDNAs (A) or indicated X11 cDNA (F); then NEP, ECE, IDE, Fe65, actin, AICDC50, AICDC59, and X11 expressions were
measured by Western blot. In (D), AICDC59-like immunoreactivity was assessed by immunohistochemistry after transfection of AICDC59
alone (upper panels) or together with Fe65 and Tip60 (lower panels) in HEK293 cells. Note the increase of AICDC59 expression and the
nuclear redistribution of AICDC59-like immunoreactivity (shown by merge with nuclear DAPI label [left panels]) triggered by Fe65 and Tip60
cDNA transfections. (E) NEP mRNA (upper panel) and activity (lower panel) are decreased by Fe65 deficiency in fibroblasts. Bars in (E) and
(F) represent the mean ± SEM of four (E) or five (F) independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001.shown), a phenotype further potentiated by Fe65 andip60 (142.9% ± 19% and 174.9% ± 19% for AICDC50+
e65+Tip60 and AICDC59+Fe65+Tip60 versus control,
espectively, n = 3; p < 0.05). Fe65 and Tip60 (either
lone or in combination with AICDs) had no effect on
he expressions of endothelin-converting enzyme and
nsulin-degrading enzyme in PS+/+ fibroblasts and
EK293 cells (Figure 5A), a result that is in agreement
ith the experiments described above showing that the
resenilin-dependent enhancement of Aβ degradation
s specific to neprilysin (see Figure 1). In order to exam-
ne whether Fe65 could be a limiting factor for expres-
ion of neprilysin, we examined the activity of neprilysin
n p97Fe65-deficient mice fibroblasts (Wang et al.,
004). Abolition of p97Fe65 diminished neprilysin activ-
ty (52% ± 5.9% of decrease in Fe65−/− versus control
ibroblasts, n = 4; p < 0.01) (Figure 5E) and mRNA ex-
ression (27% ± 1.5% of decrease in Fe65−/− versus
ontrol fibroblasts, n = 3; p < 0.005) (Figure 5E).
Interestingly, the overexpression of X11α, X11β, and
11γ that triggers opposite effects on Aβ recovery
hen compared to Fe65 (Borg et al., 1998; Sastre et al.,
998; Lee et al., 2003) decreased neprilysin activity in
EK293 cells (40%, 46%, and 47% of inhibition of nep-
ilysin activity compared to control for X11α, X11β, and
11γ, respectively, n = 5) (Figure 5F).
APP and APLPs Complement Each Other
o Control Neprilysin In Vitro and In Vivo
o test whether the endogenous PS-dependent prod-uct controlling neprilysin activity was indeed AICD, we
Presenilins Regulate Neprilysin Transcription
547examined neprilysin activity and expression in βAPP-
deficient fibroblasts. βAPP−/− fibroblasts exhibit a simi-
larly significant reduction of neprilysin activity (30% ±
7.6% [n = 7; p < 0.005; Figure 6A] and 31% ± 6.7% [n =
3; p < 0.001; Figure 6B] reduction in homogenates and
intact cells, respectively, versus control activity) that
fully matched the reduction in NEP expression (26.1% ±
6.9% reduction, n = 3; p < 0.05; Figures 6C and 6D).
Neprilysin activity is fully restored by βAPP cDNA trans-
fection in APP−/− fibroblasts (125.6 ± 6 of control, n =
4; p < 0.01; Figure 7A). It is of interest that loss of βAPP
expression in APP−/− mouse brain triggers a significant
reduction in neprilysin activity (47% ± 3.5% in APP−/−
versus control, n = 4; p < 0.005; Figures 6E and 6F). This
suggests that derivatives of βAPP might also control
cerebral neprilysin in vivo and supports the notion that
a presenilin-dependent, γ-secretase-mediated cleav-Figure 6. NEP Expression and Activity Are Affected by APP, APLP1,
and APLP2 Deficiencies In Vitro and In Vivo and by FAD Mutations
in Brain Tissues
NEP activity in homogenates (A and E–H) or intact cells (B) and
expression (C, D, and I) were monitored as described in the Experi-
mental Procedures in the indicated single or multiple KO fibroblasts
(A–D) or in mice (E and F) or Alzheimer’s (G–I) brain tissues. (G) NEP
activity in L392V-PS1 and control brain. Activity (H) and expression
of NEP and IDE (I) in L235P-PS1 and F386S-PS1 cases (FAD), two
sporadic cases (AD), and control brains (CT). Bars in (B), (F), and
(G) represent the mean ± SEM of three to seven independent deter-
minations. Insert in (B) corresponds to RT-PCR NEP mRNA analysis
in wild-type (WT) and APP−/−APLP2−/− fibroblasts. Bars in (D) corre-
spond to the densitometric analysis of NEP expression and repre-
sent the mean ± SEM of three determinations. *p < 0.05; **p <
0.005; ***p < 0.0001.age product of APP, namely AICD, is a physiologicalregulator of neprilysin transcription both in vitro and
in vivo. However, it should be noted that the extent of
inhibition of neprilysin activity appeared lower in
βAPP−/− cells than in PS−/− fibroblasts. Therefore, we
examined whether neprilysin activity and expression
could be controlled by other βAPP-like proteins. Inter-
estingly, APLP2-deficiency in fibroblasts triggers a de-
crease in both neprilysin activity and expression that
is similar to the reductions observed in βAPP−/− cells
(Figures 6A–6D). Neprilysin activity is fully restored by
APLP2 cDNA transfection in APLP2−/− fibroblasts
(125.1 ± 6.9 of control, n = 3; p < 0.05; Figure 7A). How-
ever, the absence of both βAPP and APLP2 in fibro-
blasts resulted in an even more dramatic reduction in
neprilysin activity and expression (80% ± 2.6% reduc-
tion of activity in homogenate, n = 8; p < 0.0001; Figure
6A; 87% ± 2.% reduction of activity on intact cells, n =
6; p < 0.0001; Figure 6B; and 92% ± 0.7% reduction of
expression in APP−/−APLP2−/− versus control fibro-
blasts, n = 3; p < 0.0001; Figures 6C and 6D), while
ECE-like and IDE-like immunoreactivities remained un-
affected (not shown). Importantly, double βAPP/APLP2
deficiency also led to decreased NEP mRNA expres-
sion (30% reduction in two independent experiments,
Figure 6B [inset]). Of most interest is our observation
that cotransfection of Tip60 and Fe65 cDNAs drasti-
cally increase neprilysin activity in wild-type fibroblasts,
but not in APP−/−APLP2−/− doubly deficient fibroblasts
(Figure 7B). However, AICDC50 still potentiates trans-
activation of rNEPP1 and rNEPP2 promoters in APP−/−
APLP2−/− fibroblasts (Figure 7C).
This apparently synergistic effect led us to hypothe-
size that APP and APLP2, which have homologous C
termini, could partially complement each other for the
control of neprilysin expression. However, it should be
noted that the extent of inhibition of neprilysin activity
in brain (52% ± 9.8% in APP−/−APLP2−/− versus control,
n = 4; p < 0.05; Figure 6F) was lower than that observed
in the corresponding APP−/−APLP2−/− double knockout
fibroblasts. This could be due to another protein that
would complement APP and APLP2 function in brain
but not in fibroblasts. In this context, it is noteworthy
that, unlike in the brain, fibroblasts totally lack the βAPP
family member APLP1 (not shown). Therefore we exam-
ined whether the γ-secretase-derived fragments of
APLP1 (ALID1) and APLP2 (ALID2) could complement
neprilysin activity in APP−/−APLP2−/− fibroblasts. In-
deed, both ALID1 and ALID2 significantly increase nep-
rilysin activity in APP−/−APLP2−/− fibroblasts (142.1 ± 8,
n = 3; p < 0.005 for ALID1 and 138.8, n = 3; p < 0.005 for
ALID2, versus control; Figure 7D). The fact that APP−/−,
APP−/−APLP1−/−, and APP−/−APLP2−/− brains all display
similar reductions in neprilysin activity (Figure 6F) indi-
cate that all the members of the APP family control ce-
rebral neprilysin transcription in vivo. It should be
noted, however, that the mice brains devoid of APP,
APLP1, and APLP2 do not exhibit enhanced neprilysin
decrease when compared to double KO brains (not
shown). This suggests that, besides AICD/ALID-regu-
lated neprilysin expression, there exists also a constitu-
tive APP/APLP-independent cerebral NEP activity.
In order to establish whether the control of neprilysin
activity was restricted to the APP-related ICDs, we next
examined the putative effect of other PS-dependent
γ-secretase-mediated products. Thus, NICD is the in-
Neuron
548Figure 7. Neprilysin Activity Is Modulated by ALID1 and ALID2 but Not by NICD or E-Cad/CTF2
APP−/− (A), APLP2−/− (A), or APP−/−APLP2−/− (B–D) fibroblasts were transfected with empty pcDNA3 vector or indicated cDNAs; then NEP
activity (A, B, and D) or transactivation of rNEPP1 and rNEPP2 promoters (C) were monitored as described in the Experimental Procedures.
Error bars in (A), (B), and (D) represent the mean ± SEM of three to four independent experiments. *p < 0.05; **p < 0.005. (E–G) The indicated
fibroblasts were transiently cotransfected with 4XCBF-luciferase and β-gal cDNAs in combination with either empty vector (Ct) or cDNAs
encoding myc-tagged mENotch or myc-tagged NICD, and then mENotch and NICD (E) or NEP (F) expressions were assayed by Western
blot in the indicated cell lines, and luciferase (E) or NEP (G) activities were measured as described in the Experimental Procedures. Bars in
(E) and (G) represent the mean ± SEM of three to four independent experiments. NICD expression was also estimated by immunohistochem-
istry in PS+/+ and PS-deficient fibroblasts (H). Note a clear dense label of NICD in the nucleus. (I) E-Cad/CTF2 does not modulate NEP
expression and activity in HEK293 cells. Bars in (I) represent the mean ± SEM of seven independent experiments.tracellular fragment liberated from Notch upon γ-secre- a
ctase cleavage. To test whether NICD might also affect
neprilysin activity, we created fibroblast- and blasto- γ
Icyst-derived cell lines transiently expressing the 4XCBF-
luciferase reporter gene. In agreement with previously
published works (Herreman et al., 2000; Zhang et al., N
i2000), the transient cotransfection of mENotch (which
generates NICD upon γ-secretase cleavage) led to a ro- W
mbust transcriptional activation in wild-type fibroblasts
(Figure 7E) and blastocyst-derived cells (not shown), s
ubut not in the equivalent PS-deficient cells (Figure 7E).
However, transfection of NICD itself into wild-type and s
APS-deficient cells induced NICD protein expression
(Figure 7E), favored nuclear localization of NICD (Figure b
i7H), and increased luciferase activity (Figure 7E). These
control experiments therefore established that NICD e
twas indeed functionally expressed in our experimental
system. However, regardless of the cell system used,
mENotch and NICD were unable to restore neprilysin D
expression (Figure 7F) or neprilysin activity (Figure 7G)
in PS-deficient cells. Furthermore, the γ-secretase- S
lderived C-terminal products of E-Cadherin (E-Cad/
CTF2, Figure 7I) (Marambaud et al., 2002) and N-Cad- 2
aherin (N-Cad/CTF2, not shown) (Marambaud et al.,
2003) were also unable to affect neprilysin expression e
eand activity. Thus, unlike AICDs and ALIDs, NICD and
E- and N-Cad/CTF2 did not complement neprilysin pctivity in PS−/− cells. Taken together, these data indi-
ate that the complementation of neprilysin function by
-secretase-derived products is specifically elicited by
CDs of the βAPP family members.
eprilysin Expression and Activity Are Increased
n Alzheimer’s Brains of Genetic Origin
e have examined the neprilysin activity of control hu-
an brains and compared them to brain samples of
poradic or genetic AD origin. Neprilysin activity (Fig-
res 6G and 6H) and expression (Figure 6I) were not
tatistically different between control (CT) and sporadic
D brains, while Familial Alzheimer’s disease (FAD)
rains harboring PS1 mutations displayed higher activ-
ty (Figures 6G and 6H) and expression (Figure 6I). Inter-
stingly, insulin-degrading enzyme (IDE) was not al-
ered in FAD brains (Figure 6I).
iscussion
everal lines of evidence strongly suggest that nepri-
ysin (Hauss-Wegrzyniak and Wenk, 2002; Hama et al.,
001; Marr et al., 2003; Leissring et al., 2003; Iwata et
l., 2001), endothelin-converting enzyme (ECE; Eckman
t al., 2003), and insulin-degrading enzyme (IDE; Farris
t al., 2003) could participate in the catabolism of Aβ
eptides. We show here that neprilysin transcription,
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549expression, and enzymatic activity are dramatically re-
duced in non-neuronal and neuronal cells when they
are devoid of PS1 and PS2 and that this phenotype can
be mimicked by γ-secretase inhibitors. We have shown
that the presenilins control NEP activity at a transcrip-
tional level and that PS deficiency does not affect the
expression of IDE, ECE, or other widely distributed in-
tracellular (calpain and proteasome) or ectopeptidase
(aminopeptidase M) activities. We have also shown that
neprilysin expression and activity are significantly re-
duced in brain tissue from mice lacking PS1 and PS2
(Saura et al., 2004), indicating that the presenilins also
control cerebral neprilysin transcription, expression,
and activity in vivo. This highly specific and physiologi-
cal relationship between the presenilins and neprilysin
strongly argues for a major evolutionary and functional
role of neprilysin in the physiological catabolism of Aβ,
but does not preclude a role for other enzymes in Aβ
catabolism.
The molecular mechanisms by which the presenilins
regulate neprilysin transcription would appear, from the
data presented here, to involve the C-terminal intracel-
lular domains of APP and APLP proteins (AICDs and
ALIDs). Thus, we have clearly established that defi-
ciency of βAPP, APLP1, or APLP2 drastically reduces
neprilysin expression and activity in both fibroblasts
and in brain tissues. We have specifically shown that
Aβ42 and the γ-secretase-derived products of Notch,
E-cadherins, and N-cadherins do not support this activ-
ity. Furthermore, the Fe65 adaptor protein (which binds
to the GYENPTY motif in the cytoplasmic tail of βAPP/
AICD [King and Turner, 2004]) and Tip60 clearly potenti-
ate the AICD-induced upregulation of neprilysin in wild-
type fibroblasts but not in PS−/− and APP−/−/APLP2−/−
cells.
It has been previously reported that Fe65 and Tip60
stabilize AICD and favor its translocation to the nucleus
(Kimberly et al., 2001; Kinoshita et al., 2002). Our exper-
iments have shown that AICD translocates to the nu-
cleus in the presence of Fe65 and Tip60 and transacti-
vates neuronal and renal neprilysin promoters in TSM1
neurons, HEK293 cells, and APP−/−/APLP2−/− fibro-
blasts, respectively. Furthermore, Supergel shift analy-
sis indicates that AICDC59 interacts physically with the
neprilysin promoter in the presence of Fe65 and Tip60.
Interestingly, X11, which clearly reduces γ-secretase
cleavage of βAPP, also drastically reduces neprilysin
activity. Therefore, Fe65 and X11, which trigger oppo-
site effects on Aβ production, also elicit an opposite
phenotype in neprilysin regulation.
Altogether, the similar decrease in neprilysin activity
and expression triggered by the absence of PS or APP/
APLPs, the analogous absence of control of neprilysin
by Fe65 and Tip60 in these invalidated fibroblasts, and
the opposite phenotype observed with Fe65 and X11
all lead to the firm suggestion that the endogenous
γ-secretase-dependent fragments controlling neprilysin
are indeed AICD/ALIDs.
The redundant role of PS1 and PS2 in regulating nep-
rilysin transcription contrasts with their overlapping but
not redundant roles in modulating Aβ peptide and
Notch signaling. Thus, PS2 deficiency alone does not
affect γ-secretase-mediated production of Aβ or Notch
in vivo (Herreman et al., 1999). However, PS1 deficiencydrastically reduces both Aβ production and Notch sig-
naling (De Strooper et al., 1998). We hypothesize that in
PS1−/− fibroblasts and brain tissue, APLP1 and APLP2
could undergo γ-secretase-like cleavage by residual
endogenous PS2, thus complementing AICD function,
and thereby control neprilysin expression and activity.
Because APLPs lack the Aβ sequence (although Aβ-like
peptides seem to be generated from APLP2), their PS2-
dependent cleavage would not compensate for Aβ re-
duction that is triggered by PS1 deficiency. In this
context, the resulting phenotype would be a reduction
in Aβ production but with unaltered or weakly modified
neprilysin levels. Alternatively, we hypothesize that
there is likely to be both a constitutive (AICD-indepen-
dent) basal expression of NEP and an inducible (AICD-
dependent) expression of NEP, as suggested by resid-
ual NEP activity in triple KO (APP−/−APLP1−/−APLP2−/−)
mice brains (see Results). In PS1−/− fibroblasts and in
PS1−/− brain tissue, this constitutive level of expression,
together with the cumulative effects of residual AICD
and ALIDs generated from APP, APLP1, and APLP2 by
the PS2 γ-secretase activity, could be sufficient to
maintain neprilysin expression and activity in PS1−/−
cells. In contrast, for Notch, there is both absence of
constitutive basal expression of Notch-targeted genes
and a lack of redundancy in alternate signaling mole-
cules. Another possibility could be that NEP tran-
scription is preserved in PS1−/− cells because APLPs
γ-secretase cleavage is not affected to the same extent
as APP by PS1 deficiency. However, to our knowledge,
there is currently no data to support the notion that
PS1 and PS2 have differential/preferential effects on
γ-secretase cleavage of APP, APLP1, and APLP2.
The experiments described here do more than simply
confirm the previously and widely held suspicion that
AICD, like NICD, might act as a signaling molecule in-
volved in transcriptional activation. The experiments
here depict an elegant and unusual mechanism by
which Aβ levels are controlled. Thus, βAPP is proteolyti-
cally processed by presenilin-dependent γ-secretase,
which generates two distinct types of catabolites, Aβ
and AICD (Figure 8). One of these products, AICD, then
controls the lifetime of the other product, Aβ, by selec-
tively activating the transcription of an enzyme (nepri-
lysin) capable of degrading that other product. Thus,
γ-secretase activity directly controls Aβ production and
then indirectly modulates its degradation. To our knowl-
edge, a similar “self-contained” mechanism for regulat-
ing the degradation of enzyme products has not been
described previously; (NB: this does not preclude
AICDs from also activating other genes).
If Aβ production and degradation are tightly linked,
this raises the question of why Aβ accumulates in AD.
The net accumulation of Aβ in AD pathology likely re-
flects the cumulative effect of multiple events acting on
production, fibrillogenesis, and degradation. In many
forms of AD, especially the late-onset sporadic forms,
it has not been shown that there is increased β- and
γ-secretase activity. In fact, some have suggested that
these forms may reflect defective degradation of Aβ
(Iwata et al., 2001; Leissring et al., 2003). Therefore,
AICD levels are likely to be unchanged in these late-
onset forms of AD, and as a result, the AICD-mediated
ability to upregulate neprilysin activity would not be ef-
Neuron
550Figure 8. Model for PS-Dependent Transcriptional Activation of NEP by the βAPP-Intracellular Domain
βAPP undergoes proteolysis by various secretases. Aβ peptide is released by the sequential cleavages triggered by β- and γ-secretases in
the intracellular compartment from which it can be secreted. Once secreted, Aβ is degraded by the ectopeptidase named neprilysin (NEP), a
type II integral protein with catalytic domain facing the extracellular space. Presenilin-dependent γ-secretase cleavage is triggered by a
multiproteic complex composed of presenilin 1 (PS1) or presenilin 2 (PS2), nicastrin (NCT), Aph1, and Pen2. γ-secretase contributes to an
additional cleavage, referred to as  cleavage, that takes place slightly downstream from the γ-secretase site. The action at γ and  sites gives
rise to AICDC59 and AICDC50, respectively. AICDs interact with Fe65 and Tip60 to form an active complex activating NEP mRNA transcription.
Increased NEP activity, in turn, leads to increased Aβ degradation.ficiently brought into play to protect the brain. In con- A
ptrast, in those cases of AD arising from mutations in
APP and PS1, which activate γ-secretase and AICD c
sproduction, the principal effect is to produce longer Aβ
isoforms such as Aβ42. However, although Aβ40 is effi- a
iciently degraded by NEP, Aβ42 is degraded by NEP
both in vitro and in vivo at a 6-fold lower rate, (Shirotani o
det al., 2001). As a result, the upregulation of AICD (and
thus, NEP expression), which would be anticipated in
subjects with presenilin mutations, would not com-
E
pletely abolish the accumulation of Aβ42 in these
cases. It should be noted that, in agreement with the C
above hypothesis, neprilysin expression and activity P
(were higher only in brain tissues with familial Alzheim-
per’s disease linked to various presenilin-1 mutations,
vwhile sporadic AD cases displayed neprilysin levels
Z
similar to those exhibited by normal brain tissues (Fig- L
ures 6G–6I). Interestingly, PS1 mutations selectively af- b
fect neprilysin and do not alter insulin-degrading en- a
lzyme expression.
cThe above observations are also of direct practical
ainterest because they indicate the possibility of new av-
o
enues for controlling Aβ levels without directly affecting
γ-secretase. This latter concept is important because of
the various developmental and postnatal side-effects F
Nassociated with the inhibition of γ-secretase-mediated
wcleavage of other signaling molecules, including Notch
p(Sisodia and St. George-Hyslop, 2002; Haass and De
a
Strooper, 1999). Our work now suggests that Aβ levels i
might be modulated by directly increasing neprilysin p
wexpression, using AICD or small molecule mimics ofICD. Upregulation of neprilysin by transgenic overex-
ression, at least to modest levels, appears to be suffi-
ient to reduce brain Aβ levels and to pose few toxic
ide effects (Leissring et al., 2003). This strategy would
lso circumvent the other side effects of γ-secretase
nhibitors, including the potentially self-defeating effect
f reducing AICD and thus preventing NEP-mediated
egradation of Aβ.
xperimental Procedures
ell Culture and Transfections
rimary cultured neurons, HEK293 cells, telencephalon murine
TSM1) cell lines, blastocyst-derived cells, PS-, βAPP-, and
97Fe65-deficient fibroblasts were obtained and cultured as pre-
iously described (Vincent et al., 1996; De Strooper et al., 1999;
hang et al., 2000; Herreman et al., 2000 Armogida et al., 2001;
eissring et al., 2002; Wang et al., 2004). Mouse embryonic fibro-
lasts derived from APLP2 or APP/APLP-deficient mouse embryos
nd their littermates (Heber et al., 2000) were immortalized with the
arge T antigen of SV40. Several clonal lines were established and
ultured in DMEM/10% fetal calf serum containing 2 mM glutamine
nd 50 M β-mercaptoethanol. Transient transfections were carried
ut with DAC 30 (Eurogentec).
luorimetric Assays of Enzymatic Activities
EP activity was measured on intact cells or in cell homogenates
ith Suc-Ala-Ala-Phe-7AMC in the absence or presence of phos-
horamidon as described previously (Checler, 1993). When NEP
ctivity was measured in brain tissues, brains were homogenized
n Tris 10 mM (pH, 7.5) and centrifuged; then pellets were resus-
ended in initial volumes of homogenization buffer, and activity
as measured as above. Aminopeptidases B and M, calpain, and
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551proteasome activities were measured as previously described
(Checler, 1993).
Effect of A42 and -Secretase Inhibitors on NEP Activity
on Intact Cells
Chronic treatment of wild-type PS+/+ fibroblasts with DAPT was
achieved by addition of 2 M of the inhibitor at 0, 4, 8, 16, 20, 24,
40, 44, and 48 hr, and NEP activity was measured on intact cells at
8, 24, or 48 hr as described above. The effect of L685,458 (1 M),
DFK167 (100 M), or Aβ42 (10 ng/ml) on NEP activity was also
assessed, as indicated above, in intact wild-type fibroblasts, TSM1
neurons, and primary cultured neurons.
Coimmunoprecipitation Experiments of Endogenous
NEP and PS1
Cells were harvested in lysis buffer (50 mM Tris-HCl [pH, 7.5], 150
mM NaCl, 5 mM EDTA, 0.5% Triton X-100, and 0.5% Deoxycholate),
and then 500 g of protein was diluted in 1:2 RIPA 2X buffer and
incubated overnight at 4°C with a 2000-fold dilution of anti-nepri-
lysin 18B5 antibody together with protein A-sepharose. After cen-
trifugation, pellets were resuspended in loading buffer containing
SDS, submitted to 8% (NEP) or 12% (PS1) SDS-polyacrylamide gel
electrophoresis, and Western blot analysis. Membranes were
probed with 18B5 or anti-PS1 antibody. Immunoreactive bands
were identified with anti-rabbit peroxidase (Immunotech) or anti-
mouse peroxidase (Amersham Life Science) antibodies, followed
by electrochemiluminescence (ECL) as previously described (Alves
da Costa et al., 2002) (Amersham Pharmacia Biotech).
Subcellular Fractionation by Sucrose Gradient
Four 100 mm diameter dishes of confluent PS+/+ and PS−/− fibro-
blasts were homogenized with a dunce homogenizer in 0.25 M
sucrose and 10 mM Tris-HCl (pH, 7.4) containing 1 mM MgAc2 and
a protease inhibitor mixture (Sigma). Equal amounts of proteins (3.8
mg) of each homogenate were loaded on top of a step gradient.
After centrifugation, eleven 1 ml fractions were collected from the
top of each gradient. Proteins contained in 100 l of each fraction
were precipitated with 5 volumes of methanol overnight at 4°C,
resuspended in sample buffer, and heated for 5 min at 95°C. Nepri-
lysin was assayed by Western blot as described below. The full
characterization of cell markers has been described elsewhere (Luo
et al., 2003).
SDS/PAGE and Western Blot Analyses
NEP, β-tubulin, β actin, ECE, IDE, mENotch, NICD, βAPP, APLP1/2,
X11α, β, and γ, Fe65, and Tip60 were separated on 8% Tris-glycine
gels, while Aβ40, AICDC50, and AICDC59 were analyzed on 16.5%
Tris-tricine gels. Proteins were transferred onto Hybond-C mem-
branes and then probed with the following antibody: 18B5 (anti-
neprilysin; Dr. G. Boileau), anti-mouse ECE 32 and anti-human ECE
27 (Dr. K. Isobe), polyclonal anti-mouse IDE and anti-APLP1 and
APLP2 (EMD Biosciences), anti-human IDE (Dr. F. Authier), 9E10
anti-myc antibody (myc-tagged mENotch, NICD, AICDC50, and
AICDC59), monoclonal 22C11 (βAPP), polyclonal anti-Fe65 (Dr. L.
Mercken), anti-HA (Tip60-HA), and WO2 antibody (Aβ40). Immuno-
logical complexes were revealed with anti-rabbit peroxidase or
anti-mouse peroxidase antibodies, followed by electrochemilum-
inescence (Alves da Costa et al., 2002).
RT-PCR Analysis of NEP mRNA
Total RNA was extracted and purified with the SV Total RNA Isola-
tion System (Promega). For each RT-PCR reaction, 500 ng of RNA
was used. To amplify mouse neprilysin cDNA, the forward primer
was 5#-AGCCTCTCTGTGCTTGTCTTGC-3# and the backward primer
was 5#-CACTCATAGTAGCCT-CTGGAAGGG-3#, yielding a 614-bp
product. RT-PCR reactions were performed with the Access RT-
PCR System (Promega). The reverse transcription was done at
48°C for 45 min, followed by a denaturation step at 94°C for 2 min.
PCR reactions were performed at 94°C for 30 s, 55°C for 1 min,
and 68°C for 2 min during 40 cycles, followed by a final extension
of 7 min at 68°C. RT-PCR products were analyzed on a 1% agarose
gel stained with ethidium bromide.Cloning of AICDC50 and AICDC59
pcDNA4-AICDC59 was constructed by PCR amplification of the in-
dicated coding sequence of βAPP from pcDNA4-βAPP (Chen et al.,
2002) using the primers: 5#-TTTGGTGGAATTCATGATAGCGACA
GTGATC GTCATCACC-3# and 5#-TTTACCTCG-AGCGTTCTGCAT
CTGCTCAAAG AAC-3#. The initial methionine was artificially intro-
duced (underlined). The product was digested with EcoRI/XhoI and
subcloned into the EcoRI/XhoI site of pcDNA4 (Invitrogen) contain-
ing the coding sequence for the Myc epitope at C terminus. The
construct was confirmed by sequencing. pcDNA4-AICDC50 was
constructed using the primers 5#-TTTGGTGGAATTCATGGTGATG
CTGAAGAAGAAA-CAGTAC-3# and 5#-TTTACCTCGAGCGTT CTG
CATCTGCTCAAAGAAC-3#. The amplified product was ligated into
the pcDNA4 vector as described above.
Neuronal NEP Promoter Cloning and NEP-Luciferase
Reporter Constructs
The longest 5#-UTR for neprilysin is 98 bp, suggesting that the tran-
scription start site is at least 4452 bp from the ATG site. To clone
the promoter regulatory elements, a 2500 bp DNA fragment up-
stream of the presumed transcription start site was amplified from
human genomic DNA using the forward primer 5#-GCACTATAGC
ATTTTTAAAGG-3# and the reverse primer 5#-TGCTCCAGCCTGCT
CTCGGTC-3# (NCBI accession number AC117384, positions 71,677–
74,176, which corresponds to −6951 to –4452 from the ATG site).
The fragment was inserted into the pCR2.1 vector (Invitrogen) and
subcloned between BamHI and XbaI restriction sites into pBlue-
script vector (Stratagene) to introduce an additional XhoI site. NEP
promoter containing insert was then excised by XhoI digestion and
religated into pGL-2 vector (Promega). The subcloned fragment
was sequenced and its direction and the absence of mutational
sequences were confirmed. Two renal NEP promoter constructs
rNEPP1 (−385 bp to +147 bp) and rNEPP2 (−263 bp to +145 bp) in
frame with luciferase have been previously reported (Ishimaru et
al., 1997).
Measurements of NEP Promoter Transactivation
Neuronal and renal neprilysin promoter-luciferase constructs were
cotransfected with βgal reporter cDNA in fibroblasts, TSM1 neu-
rons, and HEK293 cells in the absence or presence of AICDs cDNA.
Forty-eight hours after transfection, luciferase and βgal activities
were measured according to previously described procedures
(Paitel et al., 2004).
Immunofluorescence Analysis
Cells (grown on glass coverslips) were transfected with AICDs or
NICD cDNAs. Forty eight hours after transfection, cells were fixed
for 20 min with 1.5% paraformaldehyde and permeabilized for 5
min with 0.1% Triton X-100. After three washes, cells were incu-
bated with the primary antibody for 4 hr at room temperature. Cells
were then washed three times with PBS and incubated for 1 hr
at room temperature with the Alexa488-labeled goat anti-mouse
antibody (Interchim). Coverslips were washed and mounted with or
without DAPI. Staining was visualized with a Leica fluorescence
microscope.
NICD Transcriptional Activity Assay
Fibroblasts were transiently cotransfected with 4XCBF-luciferase
cDNA and empty vector (pCS2), myc-tagged mENotch-coding
vectors, or NICD-coding vectors. A β-gal reporter cDNA was co-
transfected to normalize data for transfection efficiency. Forty-
eight hours after transfection, cells were rinsed, gently scraped in
PBS (pH, 7.4), and spun for 5 min at 4000 rpm. Cells were then
homogenized in 100 l of lysis buffer, and luciferase activity was
measured by the Luciferase Assay System as described (Petit et
al., 2001).
Gel Shift Assay
Electrophoretic mobility shift assays (EMSA) were performed using
a commercial DNA binding-protein detection system (Promega,
Charbonnières, France). In brief, PCR fragments covering three dis-
tinct regions of the rNEPP1 promoter were obtained using the fol-
lowing primer pairs 5#AAGCTTGACCGAGAGC3#/5#CGACACATCC
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552CGACC3# raising a 295 bp probe, 5#GGAACCTCCCCCAAGTCC3#/ J
S5#CCTTTCTCCCTCAGC3# (219 bp probe), and 5#GGTCGGGATGTG
TCG3#/5#CAGTAGCGGCTCCTTCC3# (301 bp probe); then the frag- J
ments were end labeled using [32P]ATP (6000 Ci/mmol, ICN Bio- B
medicals, Orsay, France). For the preparation of nuclear extracts, R
HEK293 cells were cultivated in 100 mm diameter dishes and tran- t
siently transfected with 12 g cDNA of either empty pcDNA3 vector C
or a mix of myc-tagged-AICDC59 (6 g), TIP60 (3 g), and Fe65 (3
B
g) by means of DAC30 reactive as previously described. Forty-
H
eight hours after transfection, cells were harvested and nuclear ex-
b
tracts were prepared according to the Current Protocols in Molecu-
a
lar Biology (Ausubel et al., 2002). Binding reactions containing nuclear
Cextracts (10 g) were performed at 37°C, using the shorter 219 bp
oprobe according to the manufacturer’s directions. Then protein-
1DNA complexes were resolved by electrophoresis through 7% na-
tive polyacrylamide gels in buffer containing 5mM Tris (pH, 8.3) and C
38 mM Glycine for 3 hr at 300V. Gels were dried and autoradio- f
graphed on a BAS-1500 phosphorimager (Fujifilm, Tokyo, Japan). 8
The specificity of the above described reactions were verified by C
Supershift gel assay corresponding to the preincubation of nuclear i
extracts with either anti-myc (specific) or anti-rabbit (nonspecific) g
antibodies before allowing the binding reactions and subsequent S
incorporation of the labeled probe.
C
t
Normal and Pathological Human Brain Tissues
CAll brain samples correspond to frontal cortices. Samples from
WRouen include a control brain (female, 74 years) and one Familial
iAD brain (female, 51 years, Leu392Val-PS1 mutation). Samples
from la Pitié Salpêtrière (Paris) correspond to two control brains
C(males, 72 and 55 years), two sporadic AD brains (females, 75 and
D82 years), and two Familial AD brains (female, 37 years, Leu235Pro-
gPS1 mutation; male, 44 years, Phe386Ser-PS1 mutation).
D
Statistical Analysis G
Statistical analyses were performed with PRISM Software (Graph- p
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